CompletedNCT06545916
Study of Sunobinop on Alcohol Consumption in Addiction
Medication studyAges 18+Romania + United States
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Brooklyn and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 14, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 209
- Sponsor
- Knoa Pharma LLC
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Romania
- Age range
- Over 18 Years
- Official registry ID
- NCT06545916
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
Get this study by email
Recruitment & locations
CompletedBrooklyn, United States · Columbus, United States · Baytown, United States
2 more locations
- Houston, United States
- Bucharest, Romania
Questions about this study
Who is behind this study?
The study sponsor is Knoa Pharma LLC, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Sunobinop and Placebo to match sunobinop.
Who was this study for?
Listed age limits: from 18 years.
